{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:54:48Z","timestamp":1787313288968,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Among individuals with atherosclerotic cardiovascular disease (ASCVD), type 2 diabetes mellitus (T2DM) is common and confers increased risk for morbidity and mortality. Differentiating risk is key to optimize efficiency of treatment selection. Our objective was to develop and validate a model to predict risk of major adverse cardiovascular events (MACE) comprising the first event of cardiovascular death, myocardial infarction (MI), or stroke for individuals with both T2DM and ASCVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), we used Cox proportional hazards models to predict MACE among participants with T2DM and ASCVD. All baseline covariates collected in the trial were considered for inclusion, although some were excluded immediately because of large missingness or collinearity. A full model was developed using stepwise selection in each of 25 imputed datasets, and comprised candidate variables selected in 20 of the 25 datasets. A parsimonious model with a maximum of 10 degrees of freedom was created using Cox models with least absolute shrinkage and selection operator (LASSO), where the adjusted R-square was used as criterion for selection. The model was then externally validated among a cohort of participants with similar criteria in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial. Discrimination of both models was assessed using Harrell\u2019s C-index and model calibration by the Greenwood-Nam-D\u2019Agostino statistic based on 4-year event rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1491 (10.2%) of 14,671 participants in TECOS and 130 (9.3%) in the ACCORD validation cohort (n\u2009=\u20091404) had MACE over 3 years\u2019 median follow-up. The final model included 9 characteristics (prior stroke, age, chronic kidney disease, prior MI, sex, heart failure, insulin use, atrial fibrillation, and microvascular complications). The model had moderate discrimination in both the internal and external validation samples (C-index\u2009=\u20090.65 and 0.61, respectively). The model was well calibrated across the risk spectrum\u2014from a cumulative MACE rate of 6% at 4 years in the lowest risk quintile to 26% in the highest risk quintile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients with T2DM and prevalent ASCVD, this 9-factor risk model can quantify the risk of future ASCVD complications and inform decision making for treatments and intensity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-022-01603-8","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T12:02:59Z","timestamp":1661601779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Susanna R.","family":"Stevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Segar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Lokhnygina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Standl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u2013644.","journal-title":"N Engl J Med"},{"key":"1603_CR2","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","volume":"132","author":"MA Cavender","year":"2015","unstructured":"Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015;132:923\u201331.","journal-title":"Circulation"},{"key":"1603_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11606-015-3556-3","volume":"31","author":"JS Rana","year":"2016","unstructured":"Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med. 2016;31:387\u201393.","journal-title":"J Gen Intern Med"},{"key":"1603_CR4","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407\u20131418.","journal-title":"N Engl J Med"},{"key":"1603_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1042\/CS20000335","volume":"101","author":"RJ Stevens","year":"2001","unstructured":"Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671\u20139.","journal-title":"Clin Sci (Lond)"},{"key":"1603_CR6","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","volume":"139","author":"D Fitchett","year":"2019","unstructured":"Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME Trial. Circulation. 2019;139:1384\u20131395.","journal-title":"Circulation"},{"key":"1603_CR7","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56:1925\u201333.","journal-title":"Diabetologia"},{"key":"1603_CR8","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.amjcard.2019.08.028","volume":"124","author":"TB Plante","year":"2019","unstructured":"Plante TB, Juraschek SP, Zakai NA, Tracy RP, Cushman M. Comparison of frequency of atherosclerotic cardiovascular disease events among primary and secondary prevention subgroups of the systolic blood pressure intervention trial. Am J Cardiol. 2019;124:1701\u20131706.","journal-title":"Am J Cardiol"},{"key":"1603_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"key":"1603_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.ahj.2013.09.003","volume":"166","author":"JB Green","year":"2013","unstructured":"Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166:983\u2013989 e7.","journal-title":"Am Heart J"},{"key":"1603_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0962280206074463","volume":"16","author":"S van Buuren","year":"2007","unstructured":"van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16:219\u2013242.","journal-title":"Stat Methods Med Res"},{"key":"1603_CR12","volume-title":"Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis","author":"FE Harrell","year":"2013","unstructured":"Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2013."},{"key":"1603_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987."},{"key":"1603_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","volume":"16","author":"R Tibshurani","year":"1997","unstructured":"Tibshurani R. The LASSO Method for Variable Selection in the Cox Model. Stat Med. 1997;16:385\u2013395.","journal-title":"Stat Med"},{"key":"1603_CR15","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","volume":"247","author":"FE Harrell Jr","year":"1982","unstructured":"Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543\u20136.","journal-title":"JAMA"},{"key":"1603_CR16","volume-title":"Evaluation of the performance of survival analysis models: discrimination and calibration measures","author":"RB D\u2019Agostino","year":"2003","unstructured":"D\u2019Agostino RB, Nam B-H. Evaluation of the performance of survival analysis models: discrimination and calibration measures. Handbook of Statistics, vol.\u00a023. New York: Elsevier; 2003."},{"key":"1603_CR17","first-page":"21i-33i","volume":"99","author":"JB Buse","year":"2007","unstructured":"ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99:21i-33i.","journal-title":"Am J Cardiol"},{"key":"1603_CR18","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"1603_CR19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1603_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u2013357.","journal-title":"N Engl J Med"},{"key":"1603_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u201339.","journal-title":"Lancet"},{"key":"1603_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2337\/dc14-1687","volume":"38","author":"X Zhuo","year":"2015","unstructured":"Zhuo X, Zhang P, Kahn HS, Bardenheier BH, Li R, Gregg EW. Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care. 2015;38:581\u20137.","journal-title":"Diabetes Care"},{"key":"1603_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2337\/dc11-1770","volume":"35","author":"CM Smith-Spangler","year":"2012","unstructured":"Smith-Spangler CM, Bhattacharya J, Goldhaber-Fiebert JD. Diabetes, its treatment, and catastrophic medical spending in 35 developing countries. Diabetes Care. 2012;35:319\u201326.","journal-title":"Diabetes Care"},{"key":"1603_CR24","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","volume":"72","author":"M Vaduganathan","year":"2018","unstructured":"Vaduganathan M, Sathiyakumar V, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, et al. Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. J Am Coll Cardiol. 2018;72:3370\u20133372.","journal-title":"J Am Coll Cardiol"},{"key":"1603_CR25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","volume":"76","author":"SR Das","year":"2020","unstructured":"Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76:1117\u20131145.","journal-title":"J Am Coll Cardiol"},{"key":"1603_CR26","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/heartjnl-2013-303640","volume":"99","author":"JA Dorresteijn","year":"2013","unstructured":"Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM, et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013;99:866\u201372.","journal-title":"Heart"},{"key":"1603_CR27","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program Expert Panel on Detection","year":"2002","unstructured":"National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143\u2013421.","journal-title":"Circulation"},{"key":"1603_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","volume":"121","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293\u20138.","journal-title":"Am Heart J"},{"key":"1603_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/01.CIR.83.1.356","volume":"83","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356\u201362.","journal-title":"Circulation"},{"key":"1603_CR30","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.2337\/dc08-0662","volume":"31","author":"J Cederholm","year":"2008","unstructured":"Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S; Swedish National Diabetes Register. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care. 2008;31:2038\u201343.","journal-title":"Diabetes Care"},{"key":"1603_CR31","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/dc06-1358","volume":"30","author":"RL Coleman","year":"2007","unstructured":"Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care. 2007;30:1292\u20133.","journal-title":"Diabetes Care"},{"key":"1603_CR32","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1515\/med-2018-0086","volume":"13","author":"N Kavaric","year":"2018","unstructured":"Kavaric N, Klisic A, Ninic A. Cardiovascular risk estimated by UKPDS risk engine algorithm in diabetes. Open Med (Wars). 2018;13:610\u2013617.","journal-title":"Open Med (Wars)"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01603-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T12:03:32Z","timestamp":1661601812000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01603-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01603-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,27]]},"assertion":[{"value":"4 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was designed and overseen by a steering committee, and an independent data and safety monitoring committee performed regular safety surveillance. All patients provided written informed consent. Institutional review board approval was required at all participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MWS has received personal fees\u00a0from Merck & Co.\u00a0YL has received grants from Merck, Janssen Research & Development, AstraZeneca, GlaxoSmithKline, and Bayer HealthCare AG. JBG has received grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Sanofi, and personal fees from AstraZeneca, Merck, Boehringer-Ingelheim, Sanofi\/Regeneron, and NovoNordisk. DKM has received honoraria for clinical trial leadership for Lilly US, AstraZeneca, Sanofi, Janssen, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Lexicon, Eisai, GlaxoSmithKline, CSL Behring and Esperion, and for consultancy for Afimmune, AstraZeneca, Sanofi, Lilly US, Boehringer Ingelheim, Merck & Co, Pfizer, Novo Nordisk, Applied Therapeutics, and Metavant. ES reports personal fees from the Oxford Diabetes Trials Unit, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Menarini, Merck Serono, Excemed, Novartis, NovoNordisk, and Sanofi. EDP has received grant support from Janssen, Merck, Sanofi, AstraZeneca, Genentech, and Amgen; and has had consulting associations with Bayer, Merck, Sanofi, and Janssen. RRH reports research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal fees from Anji Pharmacueticals, Bayer, Novartis and Novo Nordisk. All other authors report no disclosures or conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}